# PYLARIFY TRUVU (PIFLUFOLASTAT F-18) by Aphelion LLC: new human prescription drug listing

**Launch Signal Score:** 80/100

| Field | Value |
|---|---|
| Product | PYLARIFY TRUVU |
| Generic name | PIFLUFOLASTAT F-18 |
| NDC | 85347-001 |
| Labeler | Aphelion LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | NDA |
| Application number | NDA220089 |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Active ingredients | PIFLUFOLASTAT F-18 120 mCi/mL |
| Pharmacologic class | Radioactive Diagnostic Agent [EPC] |
| Marketing start | 2026-07-01 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- Brand or biologic launch.
- Injectable: hospital and 503B relevance.
- Class: Radioactive Diagnostic Agent [EPC].

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=85347-001). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.